Pharmacy market on alert to influx of quasi-drugs.

Published: 2001-08-01 06:59:00

Updated: 2001-08-01 06:59:00

The retail pharmacy exploded a harsh backlash against ever increasing entry of so called quasi-drugs in the market by reducing the strengths of non-prescription drugs.

The KFDA approved about 117 quasi-drugs recently converting from non-prescription drugs simply by reducing their strengths in ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK